Global allergy diagnostics and
therapeutics market is expected to reach USD 40.8 billion by 2022, according to
a new report by Grand View Research, Inc. Increasing prevalence of allergic
conditions and adoption of immunoassay as a viable diagnostic test is expected
to serve this market with lucrative future growth opportunities.
The prevalence of target
diseases such as asthma and food allergies are expected to grow over the next
seven years, supported by sedentary and dietary lifestyle habits. In addition,
rising indoor, industrial pollution, rapid urbanization in developing countries
and increasing greenhouse gas concentrations are expected to increase the
prevalence of pollen induced respiratory disorder, thereby boosting the overall
market growth over the forecast period.
Increasing incidences of
allergies has triggered the demand for sensitive, cost effective and accurate
diagnostics tools. Manufacturers in congruence with the changing customer
preferences are now engaged in constant product development. For instance, the
MeDALL allergen-chip for allergy determination is further expected to propel
market growth during the next seven years.
In depth research report on Allergy Diagnostics And
Therapeutics Market
Further key findings from the study suggest:
·
Consumables being an
indispensable diagnostic product segment sell in large volumes and therefore,
dominated the market in 2014 with revenue share of over 55.0%. In addition,
expensive nature of reagents and their frequent application in diagnostic assay
also supports the aforementioned fact.
·
Increasing demand for analyzers
and laminators for allergy diagnostics is expected to help this segment grow at
a lucrative CAGR of above 12.0% over the forecast period. Increasing awareness
pertaining to outsourcing of allergy testing services is anticipated to show
upward shift in coming years.
·
Increasing demand for minimally
invasive and allergen specific tests is anticipated to serve in vitro allergy
diagnostics market with future growth opportunities. The market is expected to grow with CAGR of
above 12.0% over the forecast period.
·
Inhaled allergens accounted for
the largest share of revenue in 2014 owing to, the growing incidences of
respiratory allergies. According to statistics published in 2012 by American
Academy of Allergy Asthma and Immunology (AAAAI), around 7.8 million children
suffered from respiratory allergies worldwide and the number is expected to
increase over the forecast period.
·
Hospitals are the largest
consumer of allergy diagnostic products. The segment is anticipated to grow
with CAGR of over 11.0% in coming years.
·
Antihistamines were the largest
allergy therapeutic segment as of 2014 with share valued at over 17.0% due to
associated advantages such as non sedating nature of drugs and minimum side
effects with use of second generation antihistamines in allergy treatment.
·
Immunotherapy vaccines are
expected to witness lucrative growth owing to extensive R&D coupled with
the introduction of sublingual immunotherapy tablets in the treatment of
allergic rhinitis. For instance, In April 2014, the U.S. FDA announced the
approval of a five-grass pollen sublingual tablet (Ex-Oralair) produced by
Stallergenes which are used in the treatment of pollen allergy.
·
Some key players of this market
include Thermo Fisher Scientific, Omega Diagnostics, Siemens Healthcare,
Stallergenes Greer, Lincoln Diagnostics, bioMerieux, HOB Biotech Group, Alcon
Laboratories, Hycor Biomedical and Hitachi Chemical Diagnostics.
·
Industry players are focusing
on introducing technologically advanced and innovative products to gain
competitive advantage. For instance, in March 2015, Stallergenes received
approval for STG 320 in Japan, which is the first sublingual immunotherapy
tablet used in the treatment of house dust mite allergy.
Grand View Research has
segmented the allergy diagnostics and therapeutics market on the basis of
product, end-use, diagnostic test, type of allergen, therapeutic class and
region:
Global Allergy Diagnostics Product Outlook (Revenue, USD
Million, 2012 - 2022)
·
Instruments
·
Consumables
·
Services
Global Allergy Diagnostics Allergen Type Outlook (Revenue,
USD Million, 2012 - 2022)
·
Food
·
Inhaled
·
Drug
·
Other
Global Allergy Diagnostics End-use Outlook (Revenue, USD
Million, 2012 - 2022)
·
Diagnostic Laboratories
·
Hospitals
·
Academic Research Institutes
Global Allergy Diagnostics Test Outlook (Revenue, USD
Million, 2012 - 2022)
·
In vivo test
·
Skin prick test
·
Intradermal test
·
Patch test
·
In vitro test
Global Allergy Therapeutics Drug Class Outlook (Revenue,
USD Million, 2012 - 2022)
·
Antihistamines
·
Decongestants
·
Corticosteroids
·
Mast cell stabilizers
·
Leukotriene Inhibitors
·
Nasal anticholinergics
·
Immunomodulators
·
Autoinjectable Epinephrine
·
Immunotherapy
Allergy Diagnostics Regional Outlook (Revenue, USD
Million, 2012 - 2022)
·
North America
·
U.S
·
Europe
·
U.K
·
Germany
·
Asia Pacific
·
Japan
·
China
·
Latin America
·
Brazil
·
MEA
·
South Africa
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment